PROM1 and cervical cancer: Patients with recurrent vulvar or cervical cancer (purple boxes) exhibited higher percentages of CD133+ CTCs (Fig. 4A, B, left panels) and absolute numbers of CD133+ CTCs (right panels, respectively) in their blood after therapy than patients without relapse (grey boxes).